AIPT Precision Therapeutics

Predictive Oncology CEO Letter to Shareholders

Predictive Oncology CEO Letter to Shareholders
EN
06/10/2020

Underlying

AIPTPrecision Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Precision Therapeutics

 PRESS RELEASE
Free
AIPT Precision Thera...

Axe Compute Appoints Christopher Miglino as Chief Executive Officer, U...

Axe Compute Appoints Christopher Miglino as Chief Executive Officer, Ushering in a New Era of Decentralized Compute PITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Axe Compute (or the “Company”) (Nasdaq: AGPU) today announced the appointment of Christopher Miglino as Chief Executive Officer, marking a pivotal development in the company’s commitment to decentralized compute and digital infrastructure, operating at the intersection of blockchain, AI, and capital markets. Mr. Miglino transitions into the CEO role following his involvement in the structuring of Axe Compute’s digital asset trea...

February 9, 2026 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Becomes Axe Compute, Expanding Into High-Performan...

Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Axe Compute Inc. (NASDAQ: AGPU) (the “Company” or “Axe Compute”) today announced that it has changed its name to Inc., with its common stock to begin trading on Nasdaq under the ticker symbol AGPU on December 12, 2025. Axe Compute will continue to operate its AI-driven drug discovery business and plans to expand its business into high-performance enterprise AI infrastructure, addressing rising global demand for predictable, scalable compute capacity acros...

December 12, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockhold...

Predictive Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement PITTSBURGH, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today announced that on December 1, 2025, the Company received a notification letter from Nasdaq notifying the Company that it regained compliance with Nasdaq's minimum stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1), w...

December 2, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Reports Third Quarter 2025 Financial Results and P...

Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy Company to host investor conference call and webcast on Monday, November 17th, at 9:00am EST PITTSBURGH, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), an AI-driven drug discovery company that has expanded its business to include a digital asset strategy focused on ATH, the native utility token of the Aethir network, today reported financial and operating results for the quarter ended September 30, 2025, and provided a corporate update. Q3 2025 and Recen...

November 14, 2025 1 EN
 PRESS RELEASE
Free
AIPT Precision Thera...

Predictive Oncology Announces Additions to Board and Leadership Team t...

Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to democratize access to AI infrastructure, today annou...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch